Core Viewpoint - The report highlights the financial performance and operational developments of Getein Biotech, indicating a decrease in revenue and profit while emphasizing ongoing innovation and market expansion efforts [1][2][3]. Financial Performance - Total assets at the end of the reporting period reached approximately CNY 3.91 billion, an increase of 5.47% compared to the previous year [3]. - Operating revenue for the first half of 2025 was approximately CNY 512.69 million, representing a decrease of 17.00% year-on-year [3]. - Total profit amounted to approximately CNY 110.53 million, down 33.49% from the previous year [3]. - Net profit attributable to shareholders was approximately CNY 93.23 million, a decrease of 28.52% year-on-year [3]. - The cash dividend proposed is CNY 0.9 per 10 shares, accounting for 41.95% of the net profit for the first half of 2025 [2]. Business Operations - The company continues to focus on its core business, with the chemical luminescence segment generating revenue of approximately CNY 150 million, a year-on-year increase of 10.64% [7]. - The company has developed 104 chemical luminescence detection projects, achieving full coverage of common clinical diseases [7]. - The Metis600 and Metis7000 automated biochemical immunoassay lines have been upgraded to enhance efficiency and adaptability for clinical needs [8][9]. - The GN7000/GN7120 automatic nucleic acid amplification analyzers have been launched, achieving significant market penetration with nearly 60 units installed since December 2024 [10]. Innovation and R&D - The company holds a total of 383 patents, including 57 invention patents, indicating a strong focus on innovation [11]. - The introduction of self-developed raw materials has increased the self-sufficiency rate of key materials to over 90% [13]. - The company is committed to expanding its product line and enhancing the performance of existing products to reduce production costs [13]. International Expansion - The company has established product entry permits in 67 countries, with nearly 2800 products approved for import [14]. - The international marketing strategy includes both online and offline channels, enhancing brand recognition and market share [14]. - The company has participated in exhibitions in Dubai and Nigeria, further promoting its global presence [14]. Quality Management - The company adheres to strict quality management standards, aligning with international regulations and certifications [15]. - A comprehensive quality management system has been established, covering all stages from R&D to delivery [15]. - The company has conducted multiple training sessions to enhance the skills of its service team, ensuring high customer satisfaction [16].

Core Viewpoint - The company held an online performance briefing on May 27, 2025, to discuss its 2024 annual and 2025 Q1 performance, addressing investor concerns and highlighting operational and financial conditions [1]. Group 1: Financial Performance - The company's gross margin for 2024 increased by 2.86 percentage points to 69.23%, attributed to supply chain management optimization and product structure adjustments, despite a decline in operating revenue [2]. - In Q1 2025, the company achieved operating revenue of 244 million yuan, with overseas conventional product revenue reaching 47 million yuan, a year-on-year increase of 66.51% [2]. Group 2: Business Strategy and Market Position - The company is responding to industry challenges such as centralized procurement and DRG policies by optimizing sales strategies and enhancing service systems to maintain stable business development [4]. - The Metis6000 fully automated biochemical immunoassay line targets secondary and lower-tier hospitals, with over 70% of installations in these facilities, indicating a clear market positioning strategy [4][5]. Group 3: Product Development and Innovation - The Metis7000 fully automated biochemical immunoassay line is in the trial production phase, aiming to enhance performance and cost-effectiveness, with a broad testing menu covering nearly 400 items [5]. - The company plans to further increase the proportion of its chemiluminescence business, which accounted for 26.72% of self-produced product revenue in 2024, growing by 31.14% year-on-year [4]. Group 4: International Expansion - The company has established a presence in 66 countries and regions, holding over 2,500 overseas registration certificates and product import permits, with a focus on expanding its market share in Europe, Asia, and Latin America [5].